NCT00209014View on ClinicalTrials.gov

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

June 30, 2006

Conditions

B-Cell LymphomaHodgkin's Disease

Interventions

DRUG

Thalidomide

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Emory University

OTHER

NCT00209014 - Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease | Biotech Hunter | Biotech Hunter